ArticleBMC cancer2025
Global, regional, and national burden of male breast cancer and predictions in the next 30 years: a systematic analysis of the global burden of disease study 2021.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Trends in male breast cancer in Spain, 1999-2023: a nationwide analysis of incidence and mortality.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Clinicopathological and Immunohistochemical Correlation of Stromal CD10 Expression in Invasive Breast Carcinoma: A Prospective Observational Study.Iranian journal of pathology · 2026Article
- Male breast cancer: from extrapolated practice to evidence-based care.The oncologist · 2026Review
- Male Breast Cancer: Bridging the Gaps of Neglect-A Global Call for Equitable Care and Inclusion.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer, the most common cancer in women, also affects men. However, detailed assessments of the disease burden and future projections for male breast cancer (MBC) remain limited.
methodsData on global male breast cancer mortality, disability-adjusted life years (DALYs), prevalence, and incidence from 1990 to 2021 were analyzed. We used the Estimated Annual Percentage Change (EAPC) to assess MBC trends and analyzed regional and age impacts on disease burden. The Slope Inequality Index (SII), Concentration Index (C-I), and Frontier analysis delineated inequalities and future trends. The Age-Period-Cohort (APC) model clarified population dynamics. We also identified risk factors and applied the ARIMA model to forecast disease burden changes over the next 30 years.
resultsBetween 1990 and 2021, MBC deaths and DALYs showed a global increase. The EAPC for deaths was 0.66 (0.56-0.76), with the middle Socio-Demographic Index (SDI) region experiencing the most significant rise at 2.0 (1.76-2.24). DALYs had an EAPC of 0.85 (0.75-0.95), and the Middle SDI region saw the most notable increase with an EAPC of 2.16 (1.89-2.42). The global prevalence and incidence also increased, with EAPCs of 2.3 (2.13-2.46) and 2.21 (2.05-2.37) respectively. Disease burden was high and decreasing in low SDI regions, but low and stable in high SDI regions. The Age-standardized rate(ASR)-Deaths correlated negatively with SDI. ASR-Prevalence showed a negative correlation with SDI when SDI was below 0.5, a positive correlation when SDI was between 0.5 and 0.8, and a negative correlation again when SDI exceeded 0.8. Disease burden increased with age initially, peaking in the 65-69 age group for deaths, prevalence, and incidence, then decreasing. DALYs peaked in the 60-64 age group. High red meat consumption was associated with increased mortality risk. Projections suggest that while the total MBC burden will rise over the next 30 years, ASR-Deaths and DALYs will decline globally, and prevalence and incidence will increase.
conclusionGlobal male breast cancer deaths and DALYs are rising. Low SDI regions bear a higher disease burden, which is decreasing over time, while high SDI regions maintain a lower, stable burden. Over the next 30 years, the total disease burden is projected to increase further. Given these trends, male breast cancer remains a significant global health concern, and emerging disease patterns must inform new control policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.